Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

医学 细胞因子释放综合征 内科学 肿瘤科 淋巴瘤 自体干细胞移植 移植 嵌合抗原受体 胃肠病学 免疫疗法 癌症
作者
Wei Liu,Wei Liu,Hesong Zou,L.P. Chen,Wenyang Huang,Rui Lv,Yan Xu,Huimin Liu,Yin Shi,Kefei Wang,Li Wang,Wenjie Xiong,Shuhui Deng,Shuhua Yi,Weiwei Sui,Guangxin Peng,Yueshen Ma,Li Wang,Lulu Lv,Jianxiang Wang,Jun Wei,Lugui Qiu,Wenting Zheng,Dehui Zou
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:12 (4): e008857-e008857 被引量:3
标识
DOI:10.1136/jitc-2024-008857
摘要

Background Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL. Methods Transplant-eligible patients with LBCL who were refractory to first-line immunochemotherapy or experiencing R/R status after salvage chemotherapy were enrolled. The study aimed to evaluate the safety and efficacy of this combinational therapy. Additionally, frozen peripheral blood mononuclear cell samples from this trial and CNCT19 monotherapy studies for R/R LBCL were used to evaluate the impact of the combination therapy on the in vivo behavior of CNCT19 cells. Results A total of 25 patients with R/R LBCL were enrolled in this study. The overall response and complete response rates were 92.0% and 72.0%, respectively. The 2-year progression-free survival rate was 62.3%, and the overall survival was 68.5% after a median follow-up of 27.0 months. No unexpected toxicities were observed. All cases of cytokine release syndrome were of low grade. Two cases (8%) experienced grade 3 or higher CAR T-cell-related encephalopathy syndrome. The comparison of CNCT19 in vivo behavior showed that patients in the combinational therapy group exhibited enhanced in vivo expansion of CNCT19 cells and reduced long-term exhaustion formation, as opposed to those receiving CNCT19 monotherapy. Conclusions The combinational therapy of HDT/ASCT and CNCT19 demonstrates impressive efficacy, improved CNCT19 behavior, and a favorable safety profile. Trial registration numbers ChiCTR1900025419 and NCT04690192 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
光芒万丈完成签到,获得积分10
1秒前
2秒前
WJ发布了新的文献求助10
9秒前
zzzjh完成签到,获得积分10
10秒前
Zdu发布了新的文献求助10
11秒前
12秒前
科研通AI5应助feng1235采纳,获得10
16秒前
张张发布了新的文献求助10
17秒前
星辰大海应助wwwsss采纳,获得10
18秒前
茹茹茹发布了新的文献求助10
18秒前
20秒前
21秒前
晨雾锁阳发布了新的文献求助30
22秒前
23秒前
24秒前
27秒前
洁净灭男完成签到,获得积分10
27秒前
111111发布了新的文献求助10
28秒前
28秒前
30秒前
kk发布了新的文献求助10
31秒前
wwwsss发布了新的文献求助10
31秒前
32秒前
Jinjin完成签到,获得积分10
33秒前
33秒前
滴滴答发布了新的文献求助10
34秒前
111111完成签到,获得积分10
35秒前
秀丽白昼发布了新的文献求助40
36秒前
Akim应助科研通管家采纳,获得10
36秒前
JamesPei应助科研通管家采纳,获得10
36秒前
领导范儿应助科研通管家采纳,获得10
37秒前
nn11发布了新的文献求助10
37秒前
科研通AI5应助科研通管家采纳,获得10
37秒前
Sky36001发布了新的文献求助10
37秒前
37秒前
ding应助科研通管家采纳,获得10
37秒前
科研通AI5应助科研通管家采纳,获得10
37秒前
酷波er应助科研通管家采纳,获得10
37秒前
37秒前
高分求助中
Mass producing individuality 600
Разработка метода ускоренного контроля качества электрохромных устройств 500
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
A Combined Chronic Toxicity and Carcinogenicity Study of ε-Polylysine in the Rat 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3824330
求助须知:如何正确求助?哪些是违规求助? 3366627
关于积分的说明 10441769
捐赠科研通 3085883
什么是DOI,文献DOI怎么找? 1697631
邀请新用户注册赠送积分活动 816410
科研通“疑难数据库(出版商)”最低求助积分说明 769640